Injectable Anticoagulant Substantially Cuts Bleeding Risk in Afib
2025年1月23日 · Testing two once-monthly doses of abelacimab against rivaroxaban (Xarelto), researchers found that abelacimab significantly reduced major or clinically relevant nonmajor bleeding at both the...
Novartis inks $925M Anthos takeover to rejoin clot-busting race
2025年2月11日 · Anthos has gone some way to showing abelacimab has an edge over the incumbents, linking the drug candidate to an 80% reduction in venous thromboembolism …
Novartis builds in cardiovascular with $3.1bn Anthos buy
2025年2月11日 · Abelacimab has already generated encouraging phase 2 data in the AZALEA-TIMI 71 trial, which compared two monthly doses of the antibody to open-label treated with …
Novartis pays $925M to reel in a startup it helped launch
2025年2月11日 · Abelacimab is a new type of anticoagulant called a Factor XI inhibitor. It’s designed to be safer than existing blood thinners like Xarelto and Eliquis, which earn their …
Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug …
2025年2月11日 · Anthos already has clinical trial results topping Xarelto. A Phase 2 test of abelacimab was stopped early in 2023 due to “overwhelming reduction in bleeding.”
Anthos' detailed mid-stage data back its anticoagulant, but can …
2025年1月23日 · Anthos Therapeutics' abelacimab shows lower bleeding risk vs Xarelto in atrial fibrillation trial, with 62% reduction in major/clinically relevant bleeds at 150mg dose
ESC22: Despite trial misses, Bayer preps phase 3 for …
5 天之前 · Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies.
New type of blood thinner significantly reduces bleeding risk in trial
2025年1月25日 · A mid-stage trial testing abelacimab from Anthos Therapeutics in patients with atrial fibrillation was stopped early due to an overwhelming reduction in bleeding compared to …
Direct Oral Anticoagulants Compared With Warfarin in Patients …
6 天之前 · The co‐occurrence of AF and VHD is common and increases the risk of stroke 17‐fold compared with those without. 6 Several previous studies have reported varying estimates of …
Over 10 years of non-vitamin K antagonist oral anticoagulants ...
1 天前 · The gastrointestinal mucosal damage attributed to NOACs is thought to be due to their localized anticoagulant effect in the gastrointestinal tract, highlighting the need for careful …
- 某些结果已被删除
